President and CEO Phytomedical Technologies.

, On encouraging results from early research phase of our first-generation anti-cancer compounds lives every day our efforts and initiated testing of our next-generation connections These phase two tests were specifically designed hard hard -treat strains of human cancer cells and the resulting outcomes has been very positive, Mr. Greg Wujek, President and CEO Phytomedical Technologies.

The reader is cautioned occure reliance on these forward-looking statements set, as these statements are numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry limits new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company’s products, technical problems with the Company’s research and products, price increases for supplies and components, litigation and administrative proceedings with the Company, the possible acquisition of new businesses or technologies that in operating losses or that do not work as expected result, unanticipated losses, the possible fluctuation and volatility of operating results of of the company’s results, financial condition and stock price, losses in litigation and settling cases occur Dilution in the Company’s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors , and other specific risks.With other factors, cholesterol levels and blood pressure, the doctor the results of syngo AHP better evaluate a patient’s stroke risk or myocardial infarction and plan a personalized prevention and treatment. At the ESC 2007, to the Congress of European Society of Cardiology Vienna 1 to 5 September 2007, Siemens Medical Solutions syngo AHP be establish restarted European.. Siemens Medical Solutions is expands portfolio out of Ultrasound Test: the syngo Arterial Health Package is calculated cardiovascular risk by measuring the intima-media thickness and determining so-called vascular age – the relative ages of of the ship.

Siemens Medical Solutions of Siemens AG is one of the worldwide largest suppliers healthcare industry. That company is known for merging innovative medical technologies, healthcare to management consulting and support services for customers known tangible sustainable clinical and financial outcomes. Recent acquisitions in the field of in the vitro diagnostic – such as Diagnostic Products Inc. And Bayer Diagnostics – mark significant milestone for the world’s first integrated diagnostics company is. Further information, see.